Intepirdine as adjunctive therapy to donepezil for mild‐to‐moderate Alzheimer's disease: A randomized, placebo‐controlled, phase 3 clinical trial (MINDSET)

INTRODUCTION: A previous phase 2b study supported the use of the 5‐HT6 receptor antagonist intepirdine as adjunctive therapy to donepezil for Alzheimer's disease (AD) dementia. A phase 3 study, MINDSET, was performed to test this hypothesis. METHODS: MINDSET was a global, double‐blind, randomiz...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Alzheimers Dement (N Y)
Autors principals: Lang, Frederick M., Mo, Yi, Sabbagh, Marwan, Solomon, Paul, Boada, Merce, Jones, Roy W., Frisoni, Giovanni B., Grimmer, Timo, Dubois, Bruno, Harnett, Mark, Friedhoff, Sarah R., Coslett, Shari, Cummings, Jeffrey L.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2021
Matèries:
Research Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8165732/
https://ncbi.nlm.nih.gov/pubmed/34095437
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/trc2.12136
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars